Biologics Contract Manufacturing Market by Product (Biosimilar, Insulin, Interferons), Platform (Mammalian, Microbial), Therapeutic Area, Scale of Operation - Global Forecast 2024-2030

Biologics Contract Manufacturing Market by Product (Biosimilar, Insulin, Interferons), Platform (Mammalian, Microbial), Therapeutic Area, Scale of Operation - Global Forecast 2024-2030


The Biologics Contract Manufacturing Market size was estimated at USD 22.82 billion in 2023 and expected to reach USD 26.53 billion in 2024, at a CAGR 16.74% to reach USD 67.44 billion by 2030.

Global Biologics Contract Manufacturing Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biologics Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biologics Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Acino International AG, ADMA Biologics, Inc., AGC Biologics, Ajinomoto Bio-Pharma Services, Avid Bioservices, Inc., Baxter International, Inc, Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation, JSR Life Sciences, LLC by JSR Group, Kemwell Biopharma Pvt. Ltd., Lonza Group Ltd., Midas Pharma GmbH, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Thermo Fisher Scientific, Inc., Toyobo Co. Ltd., Wacker Chemie AG, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage



This research report categorizes the Biologics Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
Biosimilar
Insulin
Interferons
Monoclonal Antibodies
Recombinant Hormones
Vaccines
Platform
Mammalian
Microbial
Therapeutic Area
Autoimmune Diseases
Cardiovascular Diseases
Infectious Diseases
Metabolic Diseases
Neurology
Oncology
Ophthalmology
Respiratory Disorders
Scale of Operation
Clinical
Commercial
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biologics Contract Manufacturing Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biologics Contract Manufacturing Market?
3. What are the technology trends and regulatory frameworks in the Biologics Contract Manufacturing Market?
4. What is the market share of the leading vendors in the Biologics Contract Manufacturing Market?
5. Which modes and strategic moves are suitable for entering the Biologics Contract Manufacturing Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Biologics Contract Manufacturing Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing demand for biosimilars and vaccine production
5.1.1.2. Ongoing investment activities by CMOs for capacity expansion
5.1.1.3. Key advantages such as cost and time saving offered by contract services
5.1.2. Restraints
5.1.2.1. Changing trade policies between countries
5.1.3. Opportunities
5.1.3.1. Emergence of single-use bioprocessing equipment & solutions
5.1.3.2. Rising demand for cell and gene therapies for targeted treatment
5.1.4. Challenges
5.1.4.1. Concerns over the breach of intellectual property and patents
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Biologics Contract Manufacturing Market, by Product
6.1. Introduction
6.2. Biosimilar
6.3. Insulin
6.4. Interferons
6.5. Monoclonal Antibodies
6.6. Recombinant Hormones
6.7. Vaccines
7. Biologics Contract Manufacturing Market, by Platform
7.1. Introduction
7.2. Mammalian
7.3. Microbial
8. Biologics Contract Manufacturing Market, by Therapeutic Area
8.1. Introduction
8.2. Autoimmune Diseases
8.3. Cardiovascular Diseases
8.4. Infectious Diseases
8.5. Metabolic Diseases
8.6. Neurology
8.7. Oncology
8.8. Ophthalmology
8.9. Respiratory Disorders
9. Biologics Contract Manufacturing Market, by Scale of Operation
9.1. Introduction
9.2. Clinical
9.3. Commercial
10. Americas Biologics Contract Manufacturing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Biologics Contract Manufacturing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Biologics Contract Manufacturing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AbbVie, Inc.
14.1.2. Abzena Ltd.
14.1.3. Acino International AG
14.1.4. ADMA Biologics, Inc.
14.1.5. AGC Biologics
14.1.6. Ajinomoto Bio-Pharma Services
14.1.7. Avid Bioservices, Inc.
14.1.8. Baxter International, Inc
14.1.9. Boehringer Ingelheim Biopharmaceuticals GmbH by ArisGlobal Company
14.1.10. Cambrex Corporation
14.1.11. Catalent, Inc.
14.1.12. Emergent BioSolutions, Inc.
14.1.13. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
14.1.14. JSR Life Sciences, LLC by JSR Group
14.1.15. Kemwell Biopharma Pvt. Ltd.
14.1.16. Lonza Group Ltd.
14.1.17. Midas Pharma GmbH
14.1.18. ProBioGen AG
14.1.19. Recipharm AB
14.1.20. Rentschler Biopharma SE
14.1.21. Samsung Biologics
14.1.22. Thermo Fisher Scientific, Inc.
14.1.23. Toyobo Co. Ltd.
14.1.24. Wacker Chemie AG
14.1.25. WuXi Biologics Co., Ltd.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
FIGURE 1. BIOLOGICS CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 2. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
FIGURE 3. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIOLOGICS CONTRACT MANUFACTURING MARKET DYNAMICS
FIGURE 7. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2030 (%)
FIGURE 10. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY PLATFORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 12. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
FIGURE 14. BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. BIOLOGICS CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. BIOLOGICS CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings